New trends, such as inhalative sedation or ketamine, are beginning to garner more attention |
References 1 Oddo M et al. Optimizing sedation in patients with acute brain injury. Critical Care 2016; 20:128. 2 Badenes R, De Fez M. Sedation in neurocritical units. In Khan Z( ed): Challenging Topics in Neuroanesthesia and Neurocritical Care. Springer International Publishing Switzerland 2017; 259 – 74. 3 Brummel NE, Girard. TD. Preventing delirium in the intensive care unit. Crit Care Clin 2013:29:51 – 65. 4 Otterspoor LC, Kalkman CJ, Cremer OL. Update on the propofol infusión syndrome in ICU management on patients with head injury. Curr Opin Anaesthesiol 2008; 21:544 – 51. 5 Smith HA et al. Delirium: an emerging frontier in the management of critically ill children. Crit Care Clin 2009; 25:593 – 614. 6 Kress JP et al. Daily interruption of sedative infusions in critically ill patients undergoing mechanical ventilation. N Engl J Med 2000; 342:1471 – 7. 7 Hogarth DK, Hall J. Management of sedation in mechanically ventilated patients. Curr Opin Crit Care 2004; 10:40 – 6. 8 DeJonge B et al. Using and understanding sedation scoring systems: a systematic review. Intensive Care Med 2000; 26: 275 – 86. 9 Schnakers C et al. The Nociception Coma Scale: a new tool to assess nociception in disorders of consciousness. Pain 2010; 148:215 – 9. 10 Riess ML et al. Sedation assessment in critically ill patients with bispectral index. Eur J Anesthesiol 2002; 19:18 – 22. 11 Deogaonkar A et al. Bispectral index monitoring correlates with sedation scales in braininjured patients. Crit Care Med 2004; 32:2403 – 6. 12 Ogilvie MP, Pereire BM, Ryan ML, et al. Bispectral index to monitor propofol sedation in trauma patients. J Trauma 2011; 71:1415 – 21. 13 Skoglund K et al. The neurological wake up test increases stress hormone levels in patients with severe traumatic brain injury. Crit Care Med 2012; 40:216 – 22. 14 Burry L et al. Daily sedation interruption versus no daily sedation interruption for critically ill adults patients requiring invasive mechanical ventilation. Cochrane Database Syst Rev 2014; 7: CD009176. 15 Heibok R et al. Effects of the neurological wake-up test on clinical examination, intrancranial pressure, brain metabolism and brain tissue oxygenation in severely brain-injured patients. Crit Care 2012; 16: R226. 16 Penson RT et al. Randomized placebo-controlled trial to the activity of the morphine glucuronides. Clin Pharmacol Ther 2000; 68:667 – 76. 17 Ickx B et al. Propofol infusion for induction and maintenance of anaesthesia in patients with endstage real disease. Br J Anaesth 1998; 81:854 – 60. 18 Hiraoka H et al. Changes in drug plasma concentrations of an extensively bound and highly extracted drug, propofol, in response to altered plasma binding. Clin Pharmacol Ther 2004; 75:324 – 30. 19 Servin F et al. Pharmacokinetics of propofol administered by |
continuous infusion in patients with cirrosis. Preliminary results. Anaesthesia 1988; 43:23 – 4. 20 Pentikainen PJ et al. Pharmacokinetics of midazolam following intravenous and oral administration in patients with chronic liver disease and in healthy subjects. J Clin Pharmacol 1989; 29:272 – 7. 21 Chauvin M et al. Sufentanil pharmacokinetics in patients with cirrhosis. Anesth Analg 1989; 68:1 – 4. 22 Mazoit JX et al. Pharmacokinetics of unchanged morphine in normal and cirrhotic subjects. Anesth Analg 1987; 66:296 – 8. 23 Skoglund K, Enblad P, Marklund N. Effects of the neurological wake up test in intracranial pressure and cerebral perfusion pressure in brain injured patients. Neurocrit Care 2009; 11:135 – 42. 24 Citerio G, Cormio M. Sedation in neurointensive care: advances in understanding and practice. Curr Opin Crit Care 2003; 9:120 – 6. 25 Barr J et al. Propofol dosing regimens for ICU sedation based upon an integrated pharmacikeneticpharmacodynamic model. Anesthesiology 2001; 95:324 – 33. 26 Oshima T, Karasawa F, Satoh T. Effects of propofol on cerebral blood flow and the metabolic rate of oxygen in humans. Acta Anesthesiol Scand 2002; 46:831 – 5. 27 Engelhard K, Werner C. Inhalational or intravenous anesthetics for craniotomies? Pro inhalational. Curr Opin Anaesthesiol 2006; 19:504 – 8. 28 Trescot AM et al. Opioid pharmacology. Pain Physicia 2008; 11: S133 – 53. 29 Weinbroum AA et al. Midazolam versus propofol for long-term sedation in the ICU: a randomized prospective comparison. Intensive Care Med 1997; 23:1258 – 63. 30 Power KN et al. Propofol treatment in adult refractory status epilecpticus. Mortality risk and outcome. Epilepsy Res 2011; 94:53 – 60. 31 Meierkord H et al. European Federation of Neurological Societies. EFNS guideline on the management of status epilepticus in adults. Eur J Neurol 2010; 17:348 – 55. 32 Marik PE, Varon J. The management of status epilepticus. Chest 2004; 126:582 – 91. 33 Ebert TJ et al. Sympathetic responses to induction of anesthesia in humans with propofol or etomidate. Anesthesiology1992; 76:725 – 33. 34 Gonzalez-Correa JA et al. Effects of propofol on the leukocyte nitric oxide pathway: in vitro and ex vivo studies in surgical patients. Naunyn Schmiedeberg’ s Arch Pharmacol 2008; 376:331 – 9. 35 Dorsout MF et al. Role of propofol and its solvent, intralipid, in nitric oxide induced peripherial vasodilation in dogs. Br J Anesth 2002; 89:492 – 8. 36 Samain E et al. The effect of propofol on angiotensin II-induced Ca 2(+) mobilization in aortic smooth muscle cells from normotensive and hypertensive rats. Anesth Analg 2009; 90:546 – 52. 37 Hutchens MP, Memtsoudis S, Sadovnikoff N. Propofol for sedation in neurointensive care. Neurocrit Care 2006; 4:54 – 62. 38 Roberts DJ et al. Sedation for critically ill adults with severe traumatic brain injury: a systematic review of randomized |
controlled trials. Cric Care Med 2011; 39:2743 – 51. 39 Peeters MY et al. Diseases severity is a major determinant for the pharmacodynamics of propofol in critically ill patients. Clin Pharmacol Ther 2008; 83:443 – 51. 40 Karabinis A et al. Safety and efficacy of analgesia-based sedation with remifentanil versus standard hypotic-based regimens in intesive care patients with brain injuries: a randomised, controlled trial. Crit Care 2004; 8: R268 – 80. 41 Hanley DF, Pozo M. Treatment of status epilepticus with midazolam in the critical care setting. Int J Clin Pract 2000; 54: 30 – 5. 42 Walder B, Tramer MR, Seeck M. Seizure-like phenomena and propofol: a systematic review. Neurology 2002; 58:1327 – 32. 43 Bauer TM et al. Prolonged sedation due to accumulation of conjugated metabolites of midazolam. Lancet 1995; 346: 145 – 7. 44 Grof TM, Bledsoe KA. Evaluating the use of dexmedetomidine in neurocritical care patients. Neurocrit Care 2010; 12:356 – 61. 45 Chen HI et al. Barbiturate infusion for intractable intracranial hypertension and its effect on brain oxygenation. Neurosurgery 2008; 63:880 – 6. 46 Marshall GT et al. Pentobarbital come for refractory intra-cranial hypertension after severe traumatic brain injury: mortality predictions and one-year outcomes in 55 patients. J Trauma 2010; 69:275 – 83. 47 Yahwak JA et al. Determination of a lorazepam dose threshold for using the osmol gap to monitor the propylene glycol toxicity. Pharmacotherapy 2008; 28:984 – 91. 48 Jakob SM et al. Dexmedetomidine vs. midazolam or propofol for sedation during prolonged mechanical ventilation: two randomized controlled trials. JAMA 2012; 307:1151 – 60. 49 Erdman M et al. A comparison of severe hemodynamic disturbances between dexmedetomidine and propofol for sedation in neurocritical care patients. Crit Care Med 2014; 42( 7): 1696 – 702. 50 Riker RR et al. SEDCOM( Safety and Efficacy of Dexmedetomidine Compared with Midazolam) Study Group: Dexmedetomidine vs. midazolam for sedation of critically ill patients: a randomized trial. JAMA 2009; 301:489 – 99. 51 Jakob SM et al. Dexmedetomidine for longterm sedation investigators: Dexmedetomidine vs. midazolam or propofol for sedation during prolonged mechanical ventilation: two randomized controlled trials. JAMA 2012; 307:1151 – 60. 52 Martin J et al. Evidence and consensus-based German guidelines for the management of analgesia, sedation and delirium in intensive care-short versión. Ger Med Sci 2010:8; Doc02. 53 Millane TA, Bennet E, Grounds RM. Isoflurane and propofol for long-term sedation in the intensive care unit a crossover study. Anaesthesia 1992; 47: 768 – 74. 54 Spencer EM, Willats SM. Isoflurane for prolonged sedation in the intensive care unit: efficacy and safety. Intensive Care Med 1992; 18:415 – 21. 55 Meiser A et al. Desflurane compared with propofol for postoperative sedation in the intensive care unit. Br J Anaesth |
2003; 90:273 – 80. 56 Halpenny D. Sevoflurane sedation. Can J Anaesth 2000; 47:193 – 4. 57 Ibrahim AE et al. Speed of recovery and side-effect profile of sevoflurane sedation compared with midazolam. Anesthesiology 2001; 94:87 – 94. 58 Kong KL, Willats SM, Prys- Roberts C. Isoflurane compared with midazolam for sedation in the intensive care unti. BMJ 1989:298:1277 – 80. 59 Kalenka A, Gross B, Isoflurane MH. Anesthesia elicits protein pattern changes in rat hippocampus. J Neurosurg Anesthesiol 2010; 22:144 – 54. 60 Tanzi RE, Bertram L. Twenty years of the Alzheimer ´ s disease amyloid hypothesis: a genetic perspective. Cell 2005; 120:545 – 55. 61 Selkoe DJ. Alzheimer`s disease: genes, proteins and therapy. Physiol Rev 2001; 81:741 – 66. 62 Eckenhoff RG et al. Inhaled anesthetic enhancement of amyloid-beta oligomerization and cytotoxicity. Anesthesiology 2004; 101:703 – 9. 63 Xie Z et al. The common inhalation anesthetic isoflurane induces apoptosis and increases amyloid beta protein levels. Anesthesiology 2006; 104:988 – 94. 64 Lee JJ, Li L, Jung HH, Zuo Z. Postconditioning with isoflurane reduced ischemia-induced brain injury in rats. Anesthesiology 2008; 108:1055 – 62. 65 Xie Z et al. The inhalation anesthetic isoflurane induces a vicious cycle of apoptosis and amyloid beta-protein accumulation. J Neurosci 2007; 27:1247 – 54. 66 Purruker JC, Renzland J, Uhlmann L. Volatile sedation with sevoflurane in intensive care patients with acute stroke or subarachnoid haemorrhage using AnaConDa ®: an observational study. Br J Anaesth 2015; 114: 934 – 43. 67 White PF, Way WL, Trevor AJ. Ketamine – its pharmacology and therapeutic uses. Anesthesiology 1982; 56:119 – 36. 68 Zeiler FA et al. The ketamine effect on intracranieal pressure in nontraumatic neurological illness. J Crit Care 2014; 29:1096 – 106. 69 Himmelseher S, Durieux ME. Revising a dogma: ketamine for patients with neurological injury? Anesth Analg 2005; 101:524 – 34. |
73 |
||||
HHE 2018 | hospitalhealthcare. com |